Replies to post #201167 on Amarin Corp Plc (AMRN)

[MedResCollab]

MedRes-

You’re right—that would certainly make an Advisory Committee (AC) meeting being held to discuss the Vascepa efficacy supplement a bad omen, signifying that FDA may consider the purported efficacy of Vascepa from the REDUCE-IT study as dubious. -MRC

I 100% agree with you... -Biobillionair

Better hope, as a staunch AMRN bull, that there isn't one then.

Regards,
-MRC